No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression.

Furukawa, Toshi A; Salanti, Georgia; Cowen, Philip J; Leucht, Stefan; Cipriani, Andrea (2020). No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression. Acta psychiatrica Scandinavica, 141(5), pp. 401-409. Wiley-Blackwell 10.1111/acps.13145

[img] Text
Furukawa ActaPsychiatrScand 2019_postprint.pdf - Accepted Version
Restricted to registered users only until 1 January 2021.
Available under License Publisher holds Copyright.

Download (611kB) | Request a copy
[img] Text
Furukawa ActaPsychiatrScand 2020.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (286kB) | Request a copy

BACKGROUND In fixed dose antidepressant trials, the lower range of the licensed dose achieves the optimal balance between efficacy and tolerability. Whether flexible upward titration while side effects permit provides additional benefits is unknown. METHODS We did a systematic review of placebo-controlled randomised trials that examined selective serotonin reuptake inhibitors (SSRIs), venlafaxine or mirtazapine in the acute treatment of major depression. Our primary outcome was response, defined as 50% or greater reduction in depression severity. Secondary outcomes included dropouts due to adverse effects and dropouts for any reason. We conducted random effects meta-analyses to calculate the ratios of odds ratios (RORs) between trials comparing the flexible dose titrating above the minimum licensed dose against placebo and those comparing the fixed minimum licensed dose against placebo. RESULTS We included 123 published and unpublished randomized controlled trials (29,420 participants). There was no evidence supporting efficacy of the flexible dosing over the fixed low dose of SSRIs (ROR 0.96, 95%CI: 0.73 to 1.25), venlafaxine (1.24, 0.96 to 1.60) or mirtazapine (0.77, 0.33 to 1.78). No important differences were noted for tolerability or for any subgroup analyses except the superior efficacy of venlafaxine flexible dosing between 75-150 mg over the fixed 75 mg (1.30, 1.02 to 1.65). CONCLUSION There was no evidence to support added value in terms of efficacy, tolerability or acceptability of flexibly titrating up the dosage over the minimum licensed dose of SSRIs or mirtazapine. For venlafaxine, increased efficacy can be expected by flexibly titrating up to 150 mg.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)

UniBE Contributor:

Salanti, Georgia

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0001-690X

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Andrea Flükiger-Flückiger

Date Deposited:

09 Jan 2020 16:40

Last Modified:

28 May 2020 06:16

Publisher DOI:

10.1111/acps.13145

PubMed ID:

31891415

Additional Information:

Furukawa and Salanti contributed equally to this work.

Uncontrolled Keywords:

Antidepressivee agents Fixed dosing Flexible dosing Major depressive disorder

BORIS DOI:

10.7892/boris.138093

URI:

https://boris.unibe.ch/id/eprint/138093

Actions (login required)

Edit item Edit item
Provide Feedback